| A nucleotide analogue prodrug is being developed by Gilead Sciences for the treatment of COVID-19 |
| Received its first emergency use authorization on 1 May 2020 in the USA |
| Received its first conditional approval in late May 2020 in Taiwan |
| Approved for use in patients with severe COVID-19 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.